发明公开
- 专利标题: MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS
- 专利标题(中): 激酶抑制剂细胞周期蛋白的医疗用途
-
申请号: EP07766316.9申请日: 2007-07-20
-
公开(公告)号: EP2046327A1公开(公告)日: 2009-04-15
- 发明人: PIKE, Andrew , LYONS, John Francis
- 申请人: Astex Therapeutics Limited
- 申请人地址: 436 Cambridge Science Park Milton Road Cambridge CB4 0QA GB
- 专利权人: Astex Therapeutics Limited
- 当前专利权人: Astex Therapeutics Limited
- 当前专利权人地址: 436 Cambridge Science Park Milton Road Cambridge CB4 0QA GB
- 代理机构: Hutchins, Michael Richard
- 优先权: US832678P 20060721
- 国际公布: WO2008009954 20080124
- 主分类号: A61K31/415
- IPC分类号: A61K31/415 ; A61K31/44 ; A61P13/12 ; A61P29/00 ; A61P25/00 ; A61P9/10 ; A61P9/12 ; A61P3/10
摘要:
The invention provides the use of a compound for the manufacture of a medicament for the treatment of pain, wherein the compound is a compound of the formula (0) : or a salt or tautomers or N-oxides or solvate thereof; wherein X is a group R1-A-NR4- or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO2, C=O, NR9(C=O) or O(C=O) wherein R9 is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen, hydroxy, C1-4 hydrocarbyloxy, amino, mono- or di-C1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO2; R2 is hydrogen; halogen; C1-4 alkoxy; or a C1-4 hydrocarbyl group optionally substituted by halogen, hydroxyl or C1-4 alkoxy (e.g. methoxy); R3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R4 is hydrogen or a C1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C1-4 alkoxy. The invention also provides the use of the compounds of the formula (0) for the treatment of stroke and for the treatment of polycystic kidney disease.
信息查询